Navigating the Challenges of Compounded GLP-1 Medications

This chapter explores the complexities and regulatory challenges involved in compounding medications like semaglutide amidst shortages and safety concerns. The discussion highlights the ethical implications of financial incentives in the compounding industry and the potential risks for patients. It also critiques the simplistic approach to obesity treatment that prioritizes drug access over comprehensive care.